Congestive Heart Failure & Diabetes Research Study
Researchers at UT Health San Antonio are conducting a study on how SGLT2 inhibitors affect muscle metabolism and ketone levels in people with Type 2 Diabetes and Heart Failure.
Fast Facts
Diagnosed with Congestive Heart Failure
Type 2 Diabetes
Compensation
Provided
Conducted in
San Antonio, TX
Study Background
This study is investigating how SGLT2 inhibitors affect heart function, blood sugar, and ketone levels in people with Type 2 Diabetes and Heart Failure.
This research study is exploring how certain diabetes medications, specifically SGLT2 inhibitors like Empagliflozin, impact ketone levels, muscle metabolism, and heart function in individuals with both Type 2 Diabetes and Heart Failure with reduced ejection fraction. Understanding these mechanisms may help improve treatments and outcomes for patients with these chronic conditions.
Participants will be assigned to one of two groups and receive a 12-week treatment with either Empagliflozin or a placebo, followed by an 8-day treatment with Acipimox in combination with either Empagliflozin or placebo. The study includes up to 16 visits and will involve blood tests, physical exams, MRIs, and other procedures to monitor heart function, glucose levels, and ketone production.
Study Background
This study is investigating how SGLT2 inhibitors affect heart function, blood sugar, and ketone levels in people with Type 2 Diabetes and Heart Failure.
This research study is exploring how certain diabetes medications, specifically SGLT2 inhibitors like Empagliflozin, impact ketone levels, muscle metabolism, and heart function in individuals with both Type 2 Diabetes and Heart Failure with reduced ejection fraction. Understanding these mechanisms may help improve treatments and outcomes for patients with these chronic conditions.
Participants will be assigned to one of two groups and receive a 12-week treatment with either Empagliflozin or a placebo, followed by an 8-day treatment with Acipimox in combination with either Empagliflozin or placebo. The study includes up to 16 visits and will involve blood tests, physical exams, MRIs, and other procedures to monitor heart function, glucose levels, and ketone production.
Additional Information
The study aims to better understand how SGLT2 inhibitors work in people with both Type 2 Diabetes and Heart Failure by observing changes in heart function, blood sugar levels, and ketone production.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18-80
- Diagnosed with congestive heart failure
- Diagnosed with type 2 diabetes
You’ll attend up to 16 visits in San Antonio or surrounding areas.
Visit 1 includes screening tests: bloodwork, physical exam, and DEXA scan.
You’ll be randomized to a treatment group for 12 weeks (Empagliflozin or placebo).
Several follow-up visits will measure your heart function (MRI), metabolic markers, and glucose levels.
You’ll also receive an 8-day treatment with Acipimox in combination with the original assigned treatment.
Participants will be compensated for each completed visit, with the opportunity to earn up to $2,000 for full study participation.
There is no cost for you to participate in our research study.